MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing — MORE CRT MPP  

Heart Failure Clinical Trial

Official title: MOre REsponse on Cardiac Resynchronization Therapy (CRT) With MultiPoint Pacing (MPP)

Status Terminated

Clinical Trial Summary

The purpose of this Clinical investigation is to assess the impact of the Multi Point Pacing (MPP) feature at 12 months in the treatment of patients not responding to standard Cardiac Resynchronization Therapy (CRT) after 6 months.

Clinical Trial Description

This study is designed as a prospective, randomized, multi-center trial. Data will be collected at enrollment, baseline, implant procedure, patient classification, 6 months and 12 months of follow-up. During the 6-month visit, the patient's response to CRT will be evaluated according to LVESV reduction. Patients with an LVESV reduction of at least 15% will be classified as responders. These patients will terminate their participation in the study and return to the center's standard practice. Patients with an LVESV reduction less than 15% will be classified as non-responders and the MPP feature will be activated according to randomization result and they will be followed until the 12-month visit. ;

Related Conditions & MeSH terms

• Heart Failure

• NCT number: NCT02006069
• Study type: Interventional
• Source: Abbott Medical Devices
• Status: Terminated
• Phase: N/A
• Start date: December 2013
• Completion date: May 30, 2021